Brief: UK's MHRA Approves Eisai-Biogen's Alzheimer's drug
22/08/2024 10:00
Aug 22 (Reuters) -
* UK'S MHRA: LECANEMAB LICENSED FOR ADULT PATIENTS IN EARLY
STAGES
OF ALZHEIMER’S DISEASE
* UK'S MHRA: TOGETHER WITH CONDITIONS OF LICENCE APPROVAL,
APPROPRIATE REGULATORY STANDARDS FOR LECANEMAB HAVE BEEN MET
Further company coverage: 4523.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln